Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Open-Label Study of ABT-869 in Solid Tumors (Japan)
jRCT2080220594Phase 1
- Sponsor
- Abbott Laboratories
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linifanib in Nonhematologic neoplasms, sponsored by Abbott Laboratories. Primary endpoints: Pharmacokinetics of ABT-869 and Safety and tolerability of ABT-869.
02
Drugs
linifanib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080220594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220594.